Skip to main content

Our legacy

bioMérieux was created in 1963, but our roots go all the way back to the 19th century, with Marcel Mérieux, a student of Louis Pasteur.

Have a look at the key milestone that have forged our entrepreneurial journey!

#pioneeringdiagnostics

2024

2024

bioMérieux announces the acquisition of LUMED, a software company that has developed a clinical decision support system to help hospitals optimize ant...
Read more
2023

2023

bioMérieux made an immediate £70M investment in Oxford Nanopore, the company delivering a new generation of nanopore-based molecular sensing technolog...
Read more

2023

The BIOFIRE® SPOTFIRE® System received FDA 510(k) Clearance and CLIA-Waiver. This fast and innovative PCR system can be used by non-lab professionals ...
Read more

2023

bioMérieux evolves its governance: Alexandre Mérieux becomes Executive President and Pierre Boulud is appointed Chief Executive Officer. This evolutio...
Read more
2022

2022

FDA 510(k) clearance for VITEK® MS PRIME, the new MALDI-TOF mass spectrometry identification system of bioMérieux.

2022

bioMérieux acquired Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) syste...
Read more

2022

A joint venture to fight AMR: Boehringer Ingelheim, Evotec SE and bioMérieux announced that they have formed a joint venture to create the next genera...
Read more

2022

CE-marking of VIDAS® KUBE™, a new generation automated immunoassay system for the renowned VIDAS® range. This innovation benefits clinical labs and fo...
Read more
2021

2021

Co-exclusive distribution agreement with Specific Diagnostics bioMérieux distributes Specific Diagnostic’s newly introduced SPECIFIC REVEAL® Rapid AST...
Read more

2021

CE marking of VIDAS® DENGUE NS1 Ag, VIDAS® Anti-DENGUE IgM and VIDAS® Anti-DENGUE IgG tests Innovative and fully-automated assays to diagnose dengue i...
Read more

2021

CE marking of VIDAS® NEPHROCHECK® test Innovative test to detect kidney stress in patients at risk of acute renal failure (AKI). Using VIDAS® 3 system...
Read more

2021

CE marking of TB-IGRA® test on VIDAS® Innovative and fully-automated test (Interferon-Gamma Release Assay) to diagnose latent TB infection. Performed ...
Read more
2020

2020

Launch of BIOFIRE® MYCOPLASMA Molecular biology test for mycoplasma detection in biopharmaceutical products.

2020

CE marking of SARS-COV-2 RESPI R-GENE® test Molecular biology test in the ARGENE® range for the detection of SARS-CoV-2, influenza viruses A and B, RS...
Read more

2020

CE marking of VIDAS® SARS-COV-2 IgM and SARS-COV-2 IgG Serology tests used to measure the presence of antibodies in people who have been infected with...
Read more

2020

Launch of the SARS-COV-2 R-GENE® test ARGENE® range test for the detection of SARS-CoV-2 coronavirus.

2020

EUA for the BIOFIRE® RP2.1 panel and CE-marked of the BIOFIRE® RP2.1plus panel Emergency use authorization (EUA) from the FDA for the BIOFIRE® RP2.1 p...
Read more

2020

BIOFIRE® COVID-19 test Emergency Use Authorization by the US Food and Drug Administration (FDA) of the BIOFIRE® COVID-19 test for the detection of SAR...
Read more
2019

2019

Acquistion of Invisible Sentinel (United-States) A company specialized in user-friendly molecular diagnostic tools for the rapid, accurate and reliabl...
Read more
2018

2018

CE mark for expanded VITEK® MS database The latest additions to the database used by this automated mass spectrometry microbial identification system ...
Read more

2018

Acquisition of a majority stake in Hybiome (China) The Chinese Company Suzhou Hybiome Biomedical Engineering Co.Ltd is specialized in automated immuno...
Read more

2018

Launch of the BIOFIRE® FILMARRAY® Pneumonia Panels The BIOFIRE® FILMARRAY® Pneumonia panel received 510 (k) clearance from the Food and Drug Administr...
Read more

2018

Acquisition of Astute Medical (United-States) Dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identifica...
Read more

2018

ENDOZYME® II GO launch A new innovative test for the detection of endotoxins in pharmaceutical microbiology control. The result of the combined expert...
Read more
2017

2017

FDA clearance for expanded pathogen identification capability on VITEK® MS VITEK® MS, rapid pathogen identification, has received 510(k) clearance fro...
Read more

2017

FDA 510(k) clearance for the BacT/ALERT® VIRTUO™ automated blood culture system BacT/ALERT® VIRTUO™ is the first continuously-monitoring blood culture...
Read more

2017

FDA clearance for RAPIDEC® CARBA NP test This test was developed for cases where microorganisms are resistant to carbapenems (a very broad spectrum an...
Read more

2017

Alexandre Mérieux appointed Chairman and CEO of bioMérieux After serving as CEO of bioMérieux for the last three years, Alexandre Mérieux succeeds Jea...
Read more

2017

FDA clearance for VIDAS® B•R•A•H•M•S PCTTM This automated test for the measurement of procalcitonin (PCT), a biological marker of bacterial infections...
Read more

2017

FDA clearance for BIOFIRE® FILMARRAY® RP2, CE marked for RP2 plus The Respiratory BIOFIRE® FILMARRAY® 2 (RP2) panel, enriched version of the Respirato...
Read more
2016

2016

Launch of EVISIGHT™ COMPACT A new automated diagnostic solution for microbial detection in pharmaceutical production and an intelligent incubator syst...
Read more

2016

Launch of EMAG® A new molecular biology platform for the extraction of nucleic acids (DNA, RNA) that builds on the quality, robustness and ease of use...
Read more

2016

Acquisition of Applied Maths (Belgium) bioMérieux enhances its bioinformatics capabilities with cutting-edge expertise and solutions for the smart use...
Read more

2016

FilmArray® Torch is FDA cleared with all 4 existing FilmArray® Panels and the system gets CE marked The FilmArray® Torch platform is FDA-cleared for u...
Read more

2016

Acquisition of Hyglos (Germany) Acquisition of Hyglos, a company that brings bioMérieux a unique and recognized expertise in the development and produ...
Read more

2016

Moving of our headquarters to the Campus de l'Étoile bioMérieux's Corporate functions are grouped on a new building in Marcy l’Étoile.(Lyon - France)....
Read more
2015

2015

Strategic partnership between bioMérieux and COPAN (Italia) Strategic partnership in clinical microbiology laboratory automation between bioMérieux an...
Read more

2015

Launch of GENE-UP® A new-generation PCR system for customers in the agri-food sector for the detection of microorganisms (bacteria and viruses).

2015

Launch of bioMérieux EPISEQ™ An innovative next-generation sequencing (NGS) service dedicated to the epidemiological monitoring of bacterial infection...
Read more
2014

2014

Launch of CE-marked VIRTUO™ The new generation of BacT/ALERT®, VIRTUO™ is a uniquely innovative automated blood culture microbial detection system.

2014

Acquisition of BioFire Diagnostics Inc. Acquisition of BioFire Diagnostics Inc., a privately held US-based company specialized in molecular biology.

2014

FDA clearance for the FilmArray® Gastrointestinal (GI) Panel The 22-target FilmArray® GI Panel1 allows a syndromic approach2 to the diagnosis of infec...
Read more
2013

2013

VIDAS® 3 The new generation of the VIDAS automated immunoassay platform.

2013

FDA approval of novel molecular test THxID™-BRAF A companion test for late stage metastatic melanoma tumor samples.
2012

2012

Acquisition of RAS (India) and partnership with Quanterix Acquisition of RAS, a specialist in molecular biology. Partnership with Quanterix for the de...
Read more
2011

2011

Launch of VITEK® MS Launch of VITEK® MS (used in association with the VITEK® 2 system) an automated mass spectrometry microbial identification system ...
Read more

2011

Acquisition of AES Laboratoire (France). An industrial microbiology company.

2011

Acquisition of ARGENE (France) A specialist in molecular biology.
2010

2010

Launch of Myla® middleware Myla® middleware is a software solution for the optimization of laboratory workflow and clinical information management. It...
Read more

2010

Acquisition of Meikang Biotech and of Shanghai Zenka Biotechnology. Acquisition of Meikang Biotech (China), a manufacturer of rapid tests. Acquisition...
Read more
2009

2009

Launch of PREVI® Color Gram PREVI® Color Gram for automated Gram staining.
2008

2008

Joint ventures and Acquisitions Acquisition of AB BIODISK (Sweden), a company internationally recognized for its antimicrobial resistance testing rang...
Read more
2007

2007

Acquisition of Biomedics (Spain) and of BTF (Australia) Acquisition of Biomedics, manufacturer of culture media. Acquisition of BTF, a specialist in i...
Read more
2006

2006

Acquisition of Bacterial Barcodes (USA)
2004

2004

Launches of TEMPO® and VITEK® 2 Compact TEMPO®, for automated enumeration of quality indicators (bacteria, yeast and mold) for the agri-food industry....
Read more

2004

bioMérieux is listed on the stock exchange.
2002

2002

NucliSENS EasyQ® and NucliSENS EasyQ® HIV-1 NucliSENS EasyQ®, a molecular diagnostics platform for amplification and real-time detection. NucliSENS Ea...
Read more
2001

2001

Acquisition of OrganonTeknika (Akzo Nobel, Netherlands). A pioneering company working in HIV screening and viral load measurement.
1997

1997

Launches of BacT/ALERT® 3D and VITEK® 2 BacT/ALERT® 3D an advanced automated system for microbial detection in blood and sterile body fluid samples fr...
Read more
1995

1995

VIDAS® D-Dimer Exclusion™ The first test used to rule out the diagnosis of deep vein thrombosis and pulmonary embolism to be certified by the FDA.
1992

1992

VIDAS® automated immunoassay platform adapted for industrial applications.
1991

1991

Launch of the VIDAS® with 8 initial kits Today VIDAS has 100 parameters.
1990

1990

Acquisition of the BOOM extraction and NASBA amplification technologies for molecular diagnostics.
1989

1989

Development of chromogenic media Culture media that enables identification of microbial colonies by coloring them.
1988

1988

Acquisition of Vitek Systems (United States) A world leader in automated bacterial identification.
1986

1986

Acquisition of Api Systems (La Balme, France). A specialist in bacterial identification and antibiotic susceptibility testing systems. ATB™ EXPRESSION...
Read more
1985

1985

First HIV screening test: VIRONOSTIKA® HIV anti-HTLV-III by Organon Teknika* *Organon Teknika was acquired by bioMérieux in 2001
1979

1979

ATB™ strip First ATB™ Antibiotic Susceptibility test strip by Api System* *Api System was acquired by bioMérieux in 1987
1974

1974

Launch of the Slidex® Meningitis kit. First test enabling the diagnosis of an infectious disease without prior culture, with results in 5 minutes comp...
Read more

1974

Alain Mérieux takes control of BD Mérieux, which becomes bioMérieux.
1972

1972

Production and sale of the first ready-to-use culture media in Petri plates.
1969

1969

The first toxoplasmosis detection kit and launch of miniaturized API® 20E strip The first toxoplasmosis detection kit: diagnosis of toxoplasmosis by i...
Read more
1967

1967

Launch by BD Mérieux of a fibrometer The fibrometer is added to the BD Mérieux catalog to test blood coagulation and is quickly adopted by a quarter (...
Read more
1963

1963

Establishment of BD Mérieux